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rne year after the World Congress in Barcelona in 2006
ocused attention upon potential problems with drug-
luting stents (DES), the annual meeting of the European
ociety of Cardiology convened in Vienna, September 1 to
, 2007. We summarize and attempt to place in perspective
he newly released data on continued follow-up of patients
reated with DES.
ummary of Key Presentations
he Bern group presented 2 additional abstracts on specific
ubsets (small-sized vessels and multivessel intervention)
rom the collaborative study group that involve 18,023
atients from 38 trials using bare-metal stents (BMS) and
irolimus- and paclitaxel-eluting stents (1). Although over-
ll and cardiac mortality and rates of definite stent throm-
osis associated with the use of BMS and DES are similar,
he sirolimus-eluting stents appear clinically superior to
aclitaxel-eluting stents. Comparing the need for target
esion revascularization at 4 years (hazard ratio [HR] 0.70,
5% confidence interval [CI] 0.56 to 0.84) and the rate of
yocardial infarction (HR 0.83, 95% CI 0.71 to 1.00), both
eem to be reduced with the sirolimus-eluting stent (p 
.002 and 0.045, respectively).
This collaborative network analysis predominantly stems
rom randomized clinical trial data. This type of meta-
nalysis compares stent A with stent B as well as stent C
ith stent B= (direct within-trial comparison) and infers
rom these how A and C compare (indirect between-trials
omparison). Such analysis assumes that BMS B and B= are
qually effective. This study adds to the knowledge base by
rom the *Cardiovascular Center Aalst, Aalst, Belgium; and †Harvard Medical
chool, Boston, Massachusetts. Dr. Wijns is the principal or co-principal investigator
n trials for several device (Abbott, Biosensors, Biotronik, Boston Scientific, Cappella,
onor, Cordis Johnson & Johnson, Devax, Medtronic, Orbus Neich, Sorin, Terumo,
opspin, and Volcano Therapeutics) and pharmaceutical (Bristol-Myers Squibb,
laxoSmithKline, Therabel) companies. All consulting fees, honoraria, and research
rants go to the nonprofit Cardiovascular Research Aalst Foundation, of which Dr.
ijns is a co-founder. Dr. Wijns is also a co-founder of Cardio3, a cell therapya
iotechnology start-up company.
Manuscript received October 26, 2007; accepted October 29, 2007.uggesting that significant differences exist between specific
rands of DES devices. However, the same statement may
ell hold true for BMS now that larger datasets have
ecome available and differences between devices can be-
ome apparent. Critics have argued that the superior per-
ormance of BMS used as a comparator against paclitaxel-
luting stents (B=) compared with that used for sirolimus-
luting stents (B) might have contributed to some extent to
he apparent superior performance of sirolimus- versus
aclitaxel-eluting stents. In any case, it is no longer appro-
riate to assume class effects for any feature of DES, be it
fficacy, safety, or effectiveness.
In Europe, nearly 20 different DES have received ap-
roval for market release (the CE mark), and many more
MS are available to the clinician. Given the widening
pectrum of device characteristics with respect to strut
hickness and material as well as use of various coatings or
urface modification techniques, one can no longer pool
ata from individual members of either class of device and
ssume identical performance. Implications for future trial
esign are huge with respect to the most appropriate choice
f comparator devices.
During the Hotline presentation on September 2, Stefan
ames (Uppsala, Sweden) presented an update on SCAAR
Swedish Coronary Angiography and Angioplasty Regis-
ry). Earlier publication of the 3-year follow-up of the 2003
o 2004 cohort (2) had led to the recommendation by the
wedish regulatory authorities to use DES only in the
bsence of other options, which was followed by a sharp
ecrease in DES use across the country. Extending the
ollow-up to 4 years and increasing the sample size from
4,215 to 39,432 procedures, there was no longer any
ignificant difference in mortality, myocardial infarction, or
ombined events between BMS and DES. Up to 1 year,
tent thrombosis rates seem to be higher with BMS, but
hereafter cumulative rates of stent thrombosis accrue by
.5% per year with DES use. At 3 years, the absolute
estenosis rate remains below 10% in both groups, with an
bsolute difference of 3.5% in favor of DES.
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ESC and Drug-Eluting Stents December 18/25, 2007:2431–3The strengths of this nationwide registry are the inclusion
f consecutive unselected cases with complete follow-up and
he large number of events, representative of real-world
ractice that includes “off-label” indications. Interpretation
f the data is problematic, because outcomes are essentially
riven by physician choices and patient characteristics. For
xample, the gradients in restenosis between BMS and DES
ay reflect the performance of physicians in selecting lesion
r patient subsets at higher risk of restenosis for treatment
ith DES rather than the intrinsic antirestenosis properties
f one type of device versus the other. Statistical adjustment
or these baseline differences was adequately performed, but
ne cannot account for unknown or nonregistered con-
ounders.
There was much speculation on the potential causes for
he contradictory findings with respect to the earlier 2003 to
004 report. Hypotheses included improved implantation
echnique, special attention to compliance with the pre-
cribed dual antiplatelet regimen, and/or extended duration
f therapy. It is essential to keep in mind that the proportion
f patients with DES increased over time: 22% in 2003,
6% in 2004, and 53% in 2005. Accordingly, the proportion
f DES patients with follow-up periods beyond 1 year (i.e.,
he risk period for [very] late stent thrombosis) was smaller
n the 2007 analysis, compared with the previously pub-
ished report (2). In any case, these results illustrate how
ifficult it is to monitor procedural outcomes on which to
ase regulatory decisions in the real world.
Single-center mortality data of 3 sequential cohorts of
atients treated with BMS (n  2,428), sirolimus-eluting
tents (n  856), and paclitaxel-eluting stents (n  2,835)
ere presented by Joost Daemen (Rotterdam, the Nether-
ands). Groups were allocated according to the initial
herapy. Patients and angiographic baseline characteristics
ndicate worsening of the risk profile over time. Survival was
ignificantly better at 30 days in the cohort treated with
irolimus-eluting stents. By landmark analysis from 3
onths to 4 years, there was no mortality difference between
he 3 groups, including a subset of 938 patients with
iabetes.
The same authors presented a 4-year update on the
bserved rates of definite stent thrombosis from the com-
ined Rotterdam-Bern experience in all-comer patients
96.4% complete follow-up in 8,146 patients). Angio-
raphically proven stent thrombosis continued to accrue
inearly by 0.6% per year up to a cumulative rate of 3.3%
incidence density of 1/100 patient-years).
Stent thrombosis rates up to 3 years were also reported for
he ARTS (Arterial Revascularization Therapies)-II regis-
ry, in which patients with multivessel disease were treated
ith multiple sirolimus-eluting stents. Based on Academic
esearch Consortium definitions (3), the rates were 3.3%
or definite (proven by angiography or pathology), 5.3% for
efinite and probable (myocardial infarction in the stent
rea), and 6.4% for definite, probable, and possible (any
nexplained death) stent thrombosis. Major adverse coro-ary event-free survival decreased progressively to 79% at 3
ears. However, out of 127 adverse events, only 31% could
e attributed to stent thrombosis. Similar data were pre-
ented by Juan Mieres (Buenos Aires, Argentina) on behalf
f the ERACI (Argentinian Randomized Study of Angio-
lasty vs. Surgery) III Investigators, showing a progressive
oss of benefit from DES use over 3 years in patients with
ultivessel disease, particularly in the presence of diabetes.
Lastly, during the Hotline session on September 4, P.
abriel Steg (Paris, France) reported, on behalf of the
nternational GRACE (Global Registry of Acute Coronary
vents) registry, an increased mortality with DES versus
MS for acute coronary syndromes. In 2,298 patients with
T-segment elevation myocardial infarction, in-hospital
utcome was better with DES, in keeping with the lower
isk profile of patients selected for DES implantation.
owever, mortality from 6 months after admission to 2
ears was 8.6% with use of DES, significantly (p  0.001)
reater than 1.6% with BMS. Markers of long-term risk,
uch as prior revascularization procedures, comorbidity, or
xtent of coronary disease, were more frequently present in
atients receiving DES, and the duration of dual antiplatelet
herapy was prolonged. After adjusting for the GRACE risk
core and other variables, the odds ratio for increased
ortality with DES remained unfavorable: approximately 6
p  0.002). Of note, no such increased risk was seen in the
,149 patients undergoing stent implantation for non–ST-
egment elevation myocardial infarction: mortality at 2 years
as 3.9% for BMS and 2.9% for DES (p  0.50).
Interpretation of these registry data is challenging, given
he possibility that selection biases for one or another
herapy could have an even stronger impact on outcome
han the selected device itself. Some have received these
bservations with skepticism, because no such excess in
ortality was seen in other registries, including the subset of
atients with ST-segment elevation myocardial infarction in
he SCAAR. Mechanical revascularization with stents or
ypass surgery represents a life-saving indication in patients
ith both ST- and non–ST-segment elevation myocardial
nfarction. In that case, one should not extrapolate short-
erm results of small randomized trials to practice until
onger-term follow-up data on safety are available, so as not
o jeopardize the proven survival benefit that was derived
rom the long-term analysis of FRISC (Fragmin and Fast
evascularization During Instability in Coronary Artery
isease)-II, RITA (Randomized Intervention Treatment of
ngina)-III, and other randomized trials.
ummary Statements
espite sometimes contradictory findings, a number of
onverging observations are emerging:
The efficacy–safety ratio with the use of DES appears to
depend on the balance between the early benefit, the
unquestionable antirestenosis effect, and the late hazard,
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December 18/25, 2007:2431–3 ESC and Drug-Eluting Stentsdriven by the rare but severe complication of stent
thrombosis.
Rates of stent thrombosis beyond 1 year depend on
definitions, but the problem persists and remains a source
of concern, with an incidence density of at least 1/100
patient-years that is stable for up to 4 years.
The net clinical performance profile of various stents,
DES or BMS, cannot be assumed to be identical, which
has important implications for approval of new drug–
device combinations.
iven the low rate of adverse events and the need to collect
ong-term data, interpretation of the datasets entails many
omplexities and interferences by confounding variables. It
hould not come as a surprise if reported signals, positive or
egative, seem to lack robustness.
Three major complicating issues can be identified:
Clinical symptoms such as death or myocardial infarction
are common to the disease itself and the potential
complication of its therapy using stents.
The obligatory use of prolonged systemic antiplatelet
therapy can interfere with outcome in opposing ways by
reducing the risk of stent thrombosis but at the same time
causing bleeding complications and/or morbid interac-
tions with intercurrent events.
With durations of follow-up that are extended for several
years, a number of patients will likely receive severaldevices of different types, and these cross-over cases
complicate further data interpretation. Of particular rel-
evance is the use of DES (or, in the past, vascular
brachytherapy) for treatment of restenosis in patients
initially treated with BMS.
s new drug–device combinations become available, it is
ssential that reliable data continue to be accumulated to
dvance our understanding of the benefit-risk balance of
ercutaneous revascularization using either BMS or DES,
specially over the longer term. Such an effort will require
ontinued collaboration between stakeholders across bound-
ries and frontiers.
esearch requests and correspondence: Dr. William Wijns,
ardiovascular Center Aalst, Moorselbaan 164, 9300 Aalst, Bel-
ium. E-mail: william.wijns@village.uunet.be.
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